SlideShare une entreprise Scribd logo
1  sur  14
Télécharger pour lire hors ligne
Quality of drugs manufactured in emerging
economies: Are cost containment strategies
heightening the likelihood of substandard
drugs in Canada?
CIHR BEST BRAINS EXCHANGE
FRIDAY, JANUARY 22, 2016. CIHR’S OFFICES 160 ELGIN STREET, 9TH FLOOR OTTAWA, ON
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
1
Key Questions
What regulatory, policy, and/ or governance changes are
needed to address new and increased risks?
How can Canada prevent and reduce health risks that
emerge when the pharmaceutical industry adopts
globalized production strategies?
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
2
Speakers & Assigned Topics
• Scene Setting Presentation – Challenge of substandard
drugs for public health
Mark Paxton, Chief Executive Officer, Rx-360
• Tension between the affordability and the access to drugs
that emerges due to cost containment strategies
Suzanne McGurn, Assistant Deputy Minister and
Executive Officer, Ontario Public Drug Programs
Ontario Ministry of Health and Long-Term Care
• What is driving globalized production strategies in the
pharmaceutical industry?
Ajaz S. Hussain, Executive Director, The National
Institute for Pharmaceutical Technology and
Education
• Potential risk factors that emerge, or are increased, when
drug production is performed in emerging economies
Andy Stergachis, Director, Global Medicines
Program, School of Public Health, University of
Washington
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
3
What is driving globalized
production strategies in the
pharmaceutical industry?
AJAZ S. HUSSAIN, EXECUTIVE DIRECTOR, THE NATIONAL INSTITUTE FOR PHARMACEUTICAL
TECHNOLOGY AND EDUCATION
AJAZ@NIPTE.ORG
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
4
Manufacturing in Emerging Economies for Canada,
USA, …:‘Better than Placebo’
“Rest bring data”
Application: NDA,..,
ANDA
“Scale-up & Process
Validation”
CGMP Compliance,
“Certification”
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
5
Globalization Drivers?
Manufacturing in Emerging Economies for Canada, USA,..:
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
6
COGS
Direct Materials
Beginning Inventory 0
Purchases 9,000
Direct Materials Available 9,000
Ending Direct Materials Inventory (4,000)
Direct Materials Used 5,000
Direct Labor 2,000
Factory Overhead 1,100
Total Manufacturing Cost 8,100
Add: Beginning Work-in-Process Inventory 5,000
Total Manufacturing Cost to Account For 13,100
Less: Ending Work-in-Process Inventory 4,500
Cost of Goods Manufactured 8,600
At a lower costs for
development & manufacturing
Capability to
satisfy
regulatory
requirements in
Canada, US,,..
Globalization of costs
& not accounting for
differences in quality
understanding
Served as a ‘stress test’ for the regulatory
systems in Canada, USA,…
Exposed prevailing intra- and inter-agency
heterogeneity and capacity constraints
Eroded public’s confidence in quality;
palpable increase in nocebo effects
Reminded us that complexity and
uncertainty remains underappreciated
Design, Controls, Specifications
CGMP Compliance
QMS & assurance of data integrity
Review & Inspection
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
7
“…..When the drug safety
system fails, people get sick.
Some die. It is hard to detect
harm. Some of these people are
already very vulnerable…
and proving the cause of harm from impurities,
adulteration, and counterfeits can be elusive. FDA
inspectors look for a culture of quality at manufacturing
facilities. Certainly the companies are obligated to ensure
a culture of quality and maintain vigilance as well. This
reflects a systems approach to safety. This system
approach wasn't at play here….”
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
8
http://www.spokesman.com/stories/2008/apr/23/house-
panel-criticizes-fda-on-foreign-inspections/
Congressman Shimkus
Breaches in assurance
of data integrity is a
Global Issue!
•Probe Finds Kaketsuken’s
GMP Violations “Extremely
Malicious”, MHLW to
Impose Penalty(3 Dec.
2015)
Mr. Shiozaki,
Head of MHLW
regrets they could
not find GMP
violation (Dec 8, 2015)
PMDA says
Routine GMP
Inspection to be
done without
prior notice ….8
Dec 2015
Einstein’s challenge….
we will never solve the problems
tomorrow with the same order of
consciousness we are using to
create the problems of today!
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
9
http://pj.jiho.jp/servlet/pjh/regulatory/outline/1226583374392.html
Use of foreign-sourced materials
creates vulnerabilities in the U.S.
drug supply. …FDA has been
working for over a decade to
stimulate modernization
QbD … an opportunity to reduce manufacturing
costs while ensuring that consumers receive high-
quality drug products…. with the proper strategies,
revitalize pharmaceutical manufacturing in the
United States.
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
10
http://www.pharmaceuticalonline.com/doc/cder-s-janet-woodcock-
nobody-can-really-tell-me-if-fda-inspections-are-effective-0001 and
http://www.fda.gov/NewsEvents/Testimony/ucm378343.htm
FDA/CDER/OPQ =
“Integrated”
How did we get here?
Pre-OPS to OPS to OPQ
Assuring Same
Quality Standards
to Safeguard
Clinical
Performance
Enhancing Science-
and Risk-based
Regulatory
Approaches
Transforming
Qualitative-
Quantitative and
Expertise-based
Product Quality
Informatics
Quality Metrics
Question-based
Review
New Inspection
Protocol
Integration of
Review, Inspection,
Surveillance, Policy,
and Research
Team-based
Integrated Quality
Assessment (IQA)
Program Alignment
across FDA
Encouraging
Development of
Emerging
Technology
Quality Information
BLAs/NDAs/ANDA
how does it link to
patients?
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
11
CDER Office of Pharmaceutical Quality
Immediate policy
considerations:
Appreciate
complexity and
uncertainty
• Regulatory review – ask the right questions
• An harmonized, integrated (review-inspection),
life-cycle approach to analytical & process
‘validation’
• Product risk-assessment criteria when deviations
from CGMPs occur
• Quality metrics – supply chain reliability;
distinguish between malicious and misguided
behaviors
• Focus on quality system & systems thinking –
recognize the difference between complicated vs
complex
Risk-assessment & classification
Quality Metrics
Culture of Quality
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
12
Invest in
Pharmaceutical
Technology
Research &
Education
The Nation Needs a
Comprehensive Pharmaceutical
Engineering Education and
Research System. Ajaz S.
Hussain. Pharmaceutical
Technology. September 2005
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
13
Summary
Capability to satisfy regulatory requirements in
Canada, US,…, at a lower development &
manufacturing costs.
Key drivers:
EBITDA
Exposed prevailing intra- and inter-agency
heterogeneity and capacity constraints
Globalization
of costs
Complexity and uncertainty in the assurance of
‘pharmaceutical quality’remains
underappreciated
Non-
compliance:
Global Issue
Product risk-assessment criteria & Quality
metrics – for supply chain reliability; distinguish
between malicious and misguided behaviors
Immediate
policy
considerations
Catch-up with the paradigm long-shifted:
“compounding” to “manufacturing”;
“compendia” to “statistical confidence”
Invest in
Research &
Education
Manufacturing in
Emerging Economies
for Canada, USA,..
Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016
14

Contenu connexe

Tendances

NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017
Ajaz Hussain
 

Tendances (20)

Totality of Evidence & Theraputic Equivalence 15 October 2016
Totality of Evidence & Theraputic Equivalence 15 October 2016Totality of Evidence & Theraputic Equivalence 15 October 2016
Totality of Evidence & Theraputic Equivalence 15 October 2016
 
QbR to QbD to CPV 16 February 2015
QbR to QbD to CPV 16 February 2015QbR to QbD to CPV 16 February 2015
QbR to QbD to CPV 16 February 2015
 
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
Product Quality & Patient Safety USP Workshop Mumbai 12 June 2015
 
Need for an Integrated approach to Formulation Research and Knowledge Management
Need for an Integrated approach to Formulation Research and Knowledge ManagementNeed for an Integrated approach to Formulation Research and Knowledge Management
Need for an Integrated approach to Formulation Research and Knowledge Management
 
IGPA Building a Culture of Quality Ajaz Hussain_5 Sept 2015_Rferences min
IGPA Building a Culture of Quality Ajaz Hussain_5 Sept 2015_Rferences minIGPA Building a Culture of Quality Ajaz Hussain_5 Sept 2015_Rferences min
IGPA Building a Culture of Quality Ajaz Hussain_5 Sept 2015_Rferences min
 
Good Regulators of Pharmaceuticals (GRP) 22 October 2014
Good Regulators of Pharmaceuticals (GRP) 22 October 2014Good Regulators of Pharmaceuticals (GRP) 22 October 2014
Good Regulators of Pharmaceuticals (GRP) 22 October 2014
 
FDA Trend: New Validation Strategies
FDA Trend: New Validation StrategiesFDA Trend: New Validation Strategies
FDA Trend: New Validation Strategies
 
NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017NIPTE Roadmap 2017 Discussion @ IFPAC 2017
NIPTE Roadmap 2017 Discussion @ IFPAC 2017
 
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016 Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
Pharmaceutical Quality by Design Travel Options Keynote @ Patheon QbD 2016
 
Regulatory Aspects of Continuous Pharmaceutical Manufacturing
Regulatory Aspects of Continuous Pharmaceutical ManufacturingRegulatory Aspects of Continuous Pharmaceutical Manufacturing
Regulatory Aspects of Continuous Pharmaceutical Manufacturing
 
Pharmaceutical Quality Assurance in the 21st Century, Sharper Focus Needed on...
Pharmaceutical Quality Assurance in the 21st Century, Sharper Focus Needed on...Pharmaceutical Quality Assurance in the 21st Century, Sharper Focus Needed on...
Pharmaceutical Quality Assurance in the 21st Century, Sharper Focus Needed on...
 
2004 4052 b1-09_Hussain-Arden-UK-Presentation
2004 4052 b1-09_Hussain-Arden-UK-Presentation2004 4052 b1-09_Hussain-Arden-UK-Presentation
2004 4052 b1-09_Hussain-Arden-UK-Presentation
 
Continuous Manufacturing Regulatory Update
Continuous Manufacturing Regulatory Update Continuous Manufacturing Regulatory Update
Continuous Manufacturing Regulatory Update
 
QbD and CoQ IDMA Mumbai 24 March 2015 slideshare
QbD and CoQ IDMA Mumbai 24 March 2015 slideshareQbD and CoQ IDMA Mumbai 24 March 2015 slideshare
QbD and CoQ IDMA Mumbai 24 March 2015 slideshare
 
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2
 
From Roadblocks to Roadmap 2017, with a 2020 Vision
From Roadblocks to Roadmap 2017, with a 2020 VisionFrom Roadblocks to Roadmap 2017, with a 2020 Vision
From Roadblocks to Roadmap 2017, with a 2020 Vision
 
A platform for assurance & efficiency - Ajaz at USP PCM Mumbai 2017
A platform for assurance & efficiency - Ajaz at USP PCM Mumbai 2017A platform for assurance & efficiency - Ajaz at USP PCM Mumbai 2017
A platform for assurance & efficiency - Ajaz at USP PCM Mumbai 2017
 
Dr Venkateswarlu Memorial Lecture 2015
Dr Venkateswarlu Memorial Lecture 2015Dr Venkateswarlu Memorial Lecture 2015
Dr Venkateswarlu Memorial Lecture 2015
 
Sharpen your Unique Sensing Proclivity: Dissolution is a process in mind and ...
Sharpen your Unique Sensing Proclivity: Dissolution is a process in mind and ...Sharpen your Unique Sensing Proclivity: Dissolution is a process in mind and ...
Sharpen your Unique Sensing Proclivity: Dissolution is a process in mind and ...
 
Systems Engineering of Pharmaceutical Quality by Design 18 December 2017 Alb...
Systems Engineering of  Pharmaceutical Quality by Design 18 December 2017 Alb...Systems Engineering of  Pharmaceutical Quality by Design 18 December 2017 Alb...
Systems Engineering of Pharmaceutical Quality by Design 18 December 2017 Alb...
 

En vedette

Internal migration lesson 4
Internal migration   lesson 4Internal migration   lesson 4
Internal migration lesson 4
Ms Geoflake
 
Spotlight on Migration: causes, consequences and what the AU can do
Spotlight on Migration: causes, consequences and what the AU can doSpotlight on Migration: causes, consequences and what the AU can do
Spotlight on Migration: causes, consequences and what the AU can do
IPSS-Addis
 
Voluntary and Forced Migration
Voluntary and Forced MigrationVoluntary and Forced Migration
Voluntary and Forced Migration
Arita Job
 
Session 9 migration techniques
Session 9  migration techniquesSession 9  migration techniques
Session 9 migration techniques
Papiya Mazumdar
 
International forced migration darfur
International forced migration darfurInternational forced migration darfur
International forced migration darfur
YCIS Beijing
 
Module 1.3 - Intro refugees and IDPs copy
Module 1.3 - Intro refugees and IDPs copyModule 1.3 - Intro refugees and IDPs copy
Module 1.3 - Intro refugees and IDPs copy
Benjamin Petrini
 

En vedette (17)

Internal migration lesson 4
Internal migration   lesson 4Internal migration   lesson 4
Internal migration lesson 4
 
Migration and Types of Migrations involving World migration Pattern
Migration and Types of Migrations involving World migration PatternMigration and Types of Migrations involving World migration Pattern
Migration and Types of Migrations involving World migration Pattern
 
Migration.ppt
Migration.ppt Migration.ppt
Migration.ppt
 
Migration
MigrationMigration
Migration
 
Spotlight on Migration: causes, consequences and what the AU can do
Spotlight on Migration: causes, consequences and what the AU can doSpotlight on Migration: causes, consequences and what the AU can do
Spotlight on Migration: causes, consequences and what the AU can do
 
Migration
MigrationMigration
Migration
 
Voluntary and Forced Migration
Voluntary and Forced MigrationVoluntary and Forced Migration
Voluntary and Forced Migration
 
Session 9 migration techniques
Session 9  migration techniquesSession 9  migration techniques
Session 9 migration techniques
 
IDP Presentation 2010
IDP Presentation 2010IDP Presentation 2010
IDP Presentation 2010
 
Insights on Culture of Quality What have I Learned 22 September 2015
Insights on Culture of Quality What have I Learned 22 September 2015Insights on Culture of Quality What have I Learned 22 September 2015
Insights on Culture of Quality What have I Learned 22 September 2015
 
International forced migration darfur
International forced migration darfurInternational forced migration darfur
International forced migration darfur
 
Biopharmaceutical classification system
Biopharmaceutical classification systemBiopharmaceutical classification system
Biopharmaceutical classification system
 
forced migration
forced migrationforced migration
forced migration
 
International migration
International migrationInternational migration
International migration
 
Forced migration
Forced migrationForced migration
Forced migration
 
Module 1.3 - Intro refugees and IDPs copy
Module 1.3 - Intro refugees and IDPs copyModule 1.3 - Intro refugees and IDPs copy
Module 1.3 - Intro refugees and IDPs copy
 
Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015Biosimilar Development EPTM 2015
Biosimilar Development EPTM 2015
 

Similaire à CHIR Best Brains Exchange 22 January 2016

7th annual clinical trials summit 2016
7th annual clinical trials summit 20167th annual clinical trials summit 2016
7th annual clinical trials summit 2016
Deepak Raj (2,000+Connections)
 
Data & Technology in Clinical Trials
Data & Technology in Clinical TrialsData & Technology in Clinical Trials
Data & Technology in Clinical Trials
Nassim Azzi, MBA
 
Advanced Analytics for Clinical Data Full Event Guide
Advanced Analytics for Clinical Data Full Event GuideAdvanced Analytics for Clinical Data Full Event Guide
Advanced Analytics for Clinical Data Full Event Guide
Pfizer
 

Similaire à CHIR Best Brains Exchange 22 January 2016 (20)

7th annual clinical trials summit 2016
7th annual clinical trials summit 20167th annual clinical trials summit 2016
7th annual clinical trials summit 2016
 
Data Integrity Validation Keynote Address Boston August 2016
Data Integrity Validation Keynote Address Boston August 2016Data Integrity Validation Keynote Address Boston August 2016
Data Integrity Validation Keynote Address Boston August 2016
 
Data & Technology in Clinical Trials
Data & Technology in Clinical TrialsData & Technology in Clinical Trials
Data & Technology in Clinical Trials
 
Critical Importance of Pharmaceutical Traceability in the Experience.pdf
Critical Importance of Pharmaceutical Traceability in the Experience.pdfCritical Importance of Pharmaceutical Traceability in the Experience.pdf
Critical Importance of Pharmaceutical Traceability in the Experience.pdf
 
Clinical Trials Summit 2015
Clinical Trials Summit 2015Clinical Trials Summit 2015
Clinical Trials Summit 2015
 
6th annual clinical trials summit 2015
6th annual clinical trials summit 20156th annual clinical trials summit 2015
6th annual clinical trials summit 2015
 
Pharma Magazine (Issue - 29)
Pharma Magazine (Issue - 29)Pharma Magazine (Issue - 29)
Pharma Magazine (Issue - 29)
 
Pharmaceutical Quality - The Office of
Pharmaceutical Quality -  The Office ofPharmaceutical Quality -  The Office of
Pharmaceutical Quality - The Office of
 
CRSIC Seminar Brochure 15 October 2016
CRSIC Seminar Brochure 15 October 2016CRSIC Seminar Brochure 15 October 2016
CRSIC Seminar Brochure 15 October 2016
 
CRSIC Seminar Brochure 15 october 2016, Mumbai
CRSIC Seminar Brochure 15 october 2016, MumbaiCRSIC Seminar Brochure 15 october 2016, Mumbai
CRSIC Seminar Brochure 15 october 2016, Mumbai
 
Improving Patient Safety and Quality Through Culture, Clinical Analytics, Evi...
Improving Patient Safety and Quality Through Culture, Clinical Analytics, Evi...Improving Patient Safety and Quality Through Culture, Clinical Analytics, Evi...
Improving Patient Safety and Quality Through Culture, Clinical Analytics, Evi...
 
From Deming to Orders of Consciousness
From Deming to Orders of ConsciousnessFrom Deming to Orders of Consciousness
From Deming to Orders of Consciousness
 
Generic non-biological complex drugs DIA CMC Workshop 2017
Generic non-biological complex drugs DIA CMC Workshop 2017Generic non-biological complex drugs DIA CMC Workshop 2017
Generic non-biological complex drugs DIA CMC Workshop 2017
 
Healthcare Magazine (issue - 38)
Healthcare Magazine (issue - 38)Healthcare Magazine (issue - 38)
Healthcare Magazine (issue - 38)
 
Advanced Analytics for Clinical Data Full Event Guide
Advanced Analytics for Clinical Data Full Event GuideAdvanced Analytics for Clinical Data Full Event Guide
Advanced Analytics for Clinical Data Full Event Guide
 
PBIO Investor Presentation
PBIO Investor PresentationPBIO Investor Presentation
PBIO Investor Presentation
 
How to Use Data to Improve Patient Safety: Part 2
How to Use Data to Improve Patient Safety: Part 2How to Use Data to Improve Patient Safety: Part 2
How to Use Data to Improve Patient Safety: Part 2
 
China Annual Drug Information Association Meeting
China Annual Drug Information Association MeetingChina Annual Drug Information Association Meeting
China Annual Drug Information Association Meeting
 
Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...
Adaptive Designs for Medical Device Clinical Studies  - By Compliance Global ...Adaptive Designs for Medical Device Clinical Studies  - By Compliance Global ...
Adaptive Designs for Medical Device Clinical Studies - By Compliance Global ...
 
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayPrecision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th May
 

Plus de Ajaz Hussain

Sustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's RealitiesSustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's Realities
Ajaz Hussain
 

Plus de Ajaz Hussain (20)

A Leapfrog Need and Opportunity for mAbs
A Leapfrog Need and Opportunity for mAbsA Leapfrog Need and Opportunity for mAbs
A Leapfrog Need and Opportunity for mAbs
 
SMART Quality by Design Applications Not Submissions in 2024
SMART Quality by Design Applications Not Submissions in 2024SMART Quality by Design Applications Not Submissions in 2024
SMART Quality by Design Applications Not Submissions in 2024
 
Intuitively Moving Institutions Towards Global Regulatory Resilience
Intuitively Moving Institutions Towards Global Regulatory Resilience Intuitively Moving Institutions Towards Global Regulatory Resilience
Intuitively Moving Institutions Towards Global Regulatory Resilience
 
Validation 4 for Credible Pharma 4 a Keynote for Valconnect 2023.pdf
Validation 4 for Credible Pharma 4 a Keynote for  Valconnect 2023.pdfValidation 4 for Credible Pharma 4 a Keynote for  Valconnect 2023.pdf
Validation 4 for Credible Pharma 4 a Keynote for Valconnect 2023.pdf
 
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdfSMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
SMART Triaxial Compaction, Social Form 483 and VAI or OAI to an Avenger.pdf
 
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
 
An Updating Perspective on BAD I in March Madness 2023.pdf
An Updating Perspective on BAD I in March Madness 2023.pdfAn Updating Perspective on BAD I in March Madness 2023.pdf
An Updating Perspective on BAD I in March Madness 2023.pdf
 
Mature Managers and Management of Pharmaceutical Quality and Quantities
Mature Managers and Management of Pharmaceutical Quality and QuantitiesMature Managers and Management of Pharmaceutical Quality and Quantities
Mature Managers and Management of Pharmaceutical Quality and Quantities
 
I-SMART Internal Validation for Continuous Professional Development.pdf
I-SMART Internal Validation for Continuous Professional Development.pdfI-SMART Internal Validation for Continuous Professional Development.pdf
I-SMART Internal Validation for Continuous Professional Development.pdf
 
S.M.A.R.T Pharmaceuticals 2021 -2030: AI or Human?
S.M.A.R.T Pharmaceuticals 2021 -2030: AI or Human?S.M.A.R.T Pharmaceuticals 2021 -2030: AI or Human?
S.M.A.R.T Pharmaceuticals 2021 -2030: AI or Human?
 
Sustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's RealitiesSustain and Build a Quality Culture in Today's Realities
Sustain and Build a Quality Culture in Today's Realities
 
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
Managing Pharmaceutical Quality in Traditional Paradigm and in the Emerging “...
 
Between Hello and Goodbye is Qualia: AICTE Faculty Development Program 29 M...
Between Hello and Goodbye is Qualia:  AICTE  Faculty Development Program 29 M...Between Hello and Goodbye is Qualia:  AICTE  Faculty Development Program 29 M...
Between Hello and Goodbye is Qualia: AICTE Faculty Development Program 29 M...
 
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
Design is to do good not just be and look good: Bad Design is Smoke, Good Des...
 
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbDPharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
Pharmaceutical Quality in the 21st Century, Current Status of PAT & QbD
 
Meaning making measurement maturity and management moksha
Meaning making measurement maturity and management mokshaMeaning making measurement maturity and management moksha
Meaning making measurement maturity and management moksha
 
Equivalence Assessment and Maturity of Quality Management Systems
Equivalence Assessment and Maturity of Quality Management SystemsEquivalence Assessment and Maturity of Quality Management Systems
Equivalence Assessment and Maturity of Quality Management Systems
 
Professionals and human experience: Ex[CI]perience Lessons in Excipients
Professionals and human experience: Ex[CI]perience Lessons in Excipients Professionals and human experience: Ex[CI]perience Lessons in Excipients
Professionals and human experience: Ex[CI]perience Lessons in Excipients
 
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
Compliance in the Age of Lockdowns & Disruptions: Reconciling Different Persp...
 
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
Critical Path Initiative Challenges: FDA ACPS Meeting 19 October 2004
 

Dernier

VIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 Booking
VIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 BookingVIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 Booking
VIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 Booking
dharasingh5698
 

Dernier (20)

Top Rated Pune Call Girls Bhosari ⟟ 6297143586 ⟟ Call Me For Genuine Sex Ser...
Top Rated  Pune Call Girls Bhosari ⟟ 6297143586 ⟟ Call Me For Genuine Sex Ser...Top Rated  Pune Call Girls Bhosari ⟟ 6297143586 ⟟ Call Me For Genuine Sex Ser...
Top Rated Pune Call Girls Bhosari ⟟ 6297143586 ⟟ Call Me For Genuine Sex Ser...
 
↑VVIP celebrity ( Pune ) Serampore Call Girls 8250192130 unlimited shot and a...
↑VVIP celebrity ( Pune ) Serampore Call Girls 8250192130 unlimited shot and a...↑VVIP celebrity ( Pune ) Serampore Call Girls 8250192130 unlimited shot and a...
↑VVIP celebrity ( Pune ) Serampore Call Girls 8250192130 unlimited shot and a...
 
Election 2024 Presiding Duty Keypoints_01.pdf
Election 2024 Presiding Duty Keypoints_01.pdfElection 2024 Presiding Duty Keypoints_01.pdf
Election 2024 Presiding Duty Keypoints_01.pdf
 
Night 7k to 12k Call Girls Service In Navi Mumbai 👉 BOOK NOW 9833363713 👈 ♀️...
Night 7k to 12k  Call Girls Service In Navi Mumbai 👉 BOOK NOW 9833363713 👈 ♀️...Night 7k to 12k  Call Girls Service In Navi Mumbai 👉 BOOK NOW 9833363713 👈 ♀️...
Night 7k to 12k Call Girls Service In Navi Mumbai 👉 BOOK NOW 9833363713 👈 ♀️...
 
Call Girls Sangamwadi Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Sangamwadi Call Me 7737669865 Budget Friendly No Advance BookingCall Girls Sangamwadi Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Sangamwadi Call Me 7737669865 Budget Friendly No Advance Booking
 
Antisemitism Awareness Act: pénaliser la critique de l'Etat d'Israël
Antisemitism Awareness Act: pénaliser la critique de l'Etat d'IsraëlAntisemitism Awareness Act: pénaliser la critique de l'Etat d'Israël
Antisemitism Awareness Act: pénaliser la critique de l'Etat d'Israël
 
Item # 4 - 231 Encino Ave (Significance Only).pdf
Item # 4 - 231 Encino Ave (Significance Only).pdfItem # 4 - 231 Encino Ave (Significance Only).pdf
Item # 4 - 231 Encino Ave (Significance Only).pdf
 
Just Call Vip call girls Wardha Escorts ☎️8617370543 Starting From 5K to 25K ...
Just Call Vip call girls Wardha Escorts ☎️8617370543 Starting From 5K to 25K ...Just Call Vip call girls Wardha Escorts ☎️8617370543 Starting From 5K to 25K ...
Just Call Vip call girls Wardha Escorts ☎️8617370543 Starting From 5K to 25K ...
 
Booking open Available Pune Call Girls Shukrawar Peth 6297143586 Call Hot In...
Booking open Available Pune Call Girls Shukrawar Peth  6297143586 Call Hot In...Booking open Available Pune Call Girls Shukrawar Peth  6297143586 Call Hot In...
Booking open Available Pune Call Girls Shukrawar Peth 6297143586 Call Hot In...
 
The Economic and Organised Crime Office (EOCO) has been advised by the Office...
The Economic and Organised Crime Office (EOCO) has been advised by the Office...The Economic and Organised Crime Office (EOCO) has been advised by the Office...
The Economic and Organised Crime Office (EOCO) has been advised by the Office...
 
Top Rated Pune Call Girls Hadapsar ⟟ 6297143586 ⟟ Call Me For Genuine Sex Se...
Top Rated  Pune Call Girls Hadapsar ⟟ 6297143586 ⟟ Call Me For Genuine Sex Se...Top Rated  Pune Call Girls Hadapsar ⟟ 6297143586 ⟟ Call Me For Genuine Sex Se...
Top Rated Pune Call Girls Hadapsar ⟟ 6297143586 ⟟ Call Me For Genuine Sex Se...
 
VIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 Booking
VIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 BookingVIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 Booking
VIP Call Girls Bhavnagar 7001035870 Whatsapp Number, 24/07 Booking
 
(NEHA) Call Girls Nagpur Call Now 8250077686 Nagpur Escorts 24x7
(NEHA) Call Girls Nagpur Call Now 8250077686 Nagpur Escorts 24x7(NEHA) Call Girls Nagpur Call Now 8250077686 Nagpur Escorts 24x7
(NEHA) Call Girls Nagpur Call Now 8250077686 Nagpur Escorts 24x7
 
Expressive clarity oral presentation.pptx
Expressive clarity oral presentation.pptxExpressive clarity oral presentation.pptx
Expressive clarity oral presentation.pptx
 
Get Premium Balaji Nagar Call Girls (8005736733) 24x7 Rate 15999 with A/c Roo...
Get Premium Balaji Nagar Call Girls (8005736733) 24x7 Rate 15999 with A/c Roo...Get Premium Balaji Nagar Call Girls (8005736733) 24x7 Rate 15999 with A/c Roo...
Get Premium Balaji Nagar Call Girls (8005736733) 24x7 Rate 15999 with A/c Roo...
 
Global debate on climate change and occupational safety and health.
Global debate on climate change and occupational safety and health.Global debate on climate change and occupational safety and health.
Global debate on climate change and occupational safety and health.
 
VIP Russian Call Girls in Indore Ishita 💚😋 9256729539 🚀 Indore Escorts
VIP Russian Call Girls in Indore Ishita 💚😋  9256729539 🚀 Indore EscortsVIP Russian Call Girls in Indore Ishita 💚😋  9256729539 🚀 Indore Escorts
VIP Russian Call Girls in Indore Ishita 💚😋 9256729539 🚀 Indore Escorts
 
WORLD DEVELOPMENT REPORT 2024 - Economic Growth in Middle-Income Countries.
WORLD DEVELOPMENT REPORT 2024 - Economic Growth in Middle-Income Countries.WORLD DEVELOPMENT REPORT 2024 - Economic Growth in Middle-Income Countries.
WORLD DEVELOPMENT REPORT 2024 - Economic Growth in Middle-Income Countries.
 
Zechariah Boodey Farmstead Collaborative presentation - Humble Beginnings
Zechariah Boodey Farmstead Collaborative presentation -  Humble BeginningsZechariah Boodey Farmstead Collaborative presentation -  Humble Beginnings
Zechariah Boodey Farmstead Collaborative presentation - Humble Beginnings
 
Call Girls Chakan Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Chakan Call Me 7737669865 Budget Friendly No Advance BookingCall Girls Chakan Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Chakan Call Me 7737669865 Budget Friendly No Advance Booking
 

CHIR Best Brains Exchange 22 January 2016

  • 1. Quality of drugs manufactured in emerging economies: Are cost containment strategies heightening the likelihood of substandard drugs in Canada? CIHR BEST BRAINS EXCHANGE FRIDAY, JANUARY 22, 2016. CIHR’S OFFICES 160 ELGIN STREET, 9TH FLOOR OTTAWA, ON Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 1
  • 2. Key Questions What regulatory, policy, and/ or governance changes are needed to address new and increased risks? How can Canada prevent and reduce health risks that emerge when the pharmaceutical industry adopts globalized production strategies? Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 2
  • 3. Speakers & Assigned Topics • Scene Setting Presentation – Challenge of substandard drugs for public health Mark Paxton, Chief Executive Officer, Rx-360 • Tension between the affordability and the access to drugs that emerges due to cost containment strategies Suzanne McGurn, Assistant Deputy Minister and Executive Officer, Ontario Public Drug Programs Ontario Ministry of Health and Long-Term Care • What is driving globalized production strategies in the pharmaceutical industry? Ajaz S. Hussain, Executive Director, The National Institute for Pharmaceutical Technology and Education • Potential risk factors that emerge, or are increased, when drug production is performed in emerging economies Andy Stergachis, Director, Global Medicines Program, School of Public Health, University of Washington Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 3
  • 4. What is driving globalized production strategies in the pharmaceutical industry? AJAZ S. HUSSAIN, EXECUTIVE DIRECTOR, THE NATIONAL INSTITUTE FOR PHARMACEUTICAL TECHNOLOGY AND EDUCATION AJAZ@NIPTE.ORG Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 4
  • 5. Manufacturing in Emerging Economies for Canada, USA, …:‘Better than Placebo’ “Rest bring data” Application: NDA,.., ANDA “Scale-up & Process Validation” CGMP Compliance, “Certification” Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 5
  • 6. Globalization Drivers? Manufacturing in Emerging Economies for Canada, USA,..: Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 6 COGS Direct Materials Beginning Inventory 0 Purchases 9,000 Direct Materials Available 9,000 Ending Direct Materials Inventory (4,000) Direct Materials Used 5,000 Direct Labor 2,000 Factory Overhead 1,100 Total Manufacturing Cost 8,100 Add: Beginning Work-in-Process Inventory 5,000 Total Manufacturing Cost to Account For 13,100 Less: Ending Work-in-Process Inventory 4,500 Cost of Goods Manufactured 8,600 At a lower costs for development & manufacturing Capability to satisfy regulatory requirements in Canada, US,,..
  • 7. Globalization of costs & not accounting for differences in quality understanding Served as a ‘stress test’ for the regulatory systems in Canada, USA,… Exposed prevailing intra- and inter-agency heterogeneity and capacity constraints Eroded public’s confidence in quality; palpable increase in nocebo effects Reminded us that complexity and uncertainty remains underappreciated Design, Controls, Specifications CGMP Compliance QMS & assurance of data integrity Review & Inspection Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 7
  • 8. “…..When the drug safety system fails, people get sick. Some die. It is hard to detect harm. Some of these people are already very vulnerable… and proving the cause of harm from impurities, adulteration, and counterfeits can be elusive. FDA inspectors look for a culture of quality at manufacturing facilities. Certainly the companies are obligated to ensure a culture of quality and maintain vigilance as well. This reflects a systems approach to safety. This system approach wasn't at play here….” Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 8 http://www.spokesman.com/stories/2008/apr/23/house- panel-criticizes-fda-on-foreign-inspections/ Congressman Shimkus
  • 9. Breaches in assurance of data integrity is a Global Issue! •Probe Finds Kaketsuken’s GMP Violations “Extremely Malicious”, MHLW to Impose Penalty(3 Dec. 2015) Mr. Shiozaki, Head of MHLW regrets they could not find GMP violation (Dec 8, 2015) PMDA says Routine GMP Inspection to be done without prior notice ….8 Dec 2015 Einstein’s challenge…. we will never solve the problems tomorrow with the same order of consciousness we are using to create the problems of today! Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 9 http://pj.jiho.jp/servlet/pjh/regulatory/outline/1226583374392.html
  • 10. Use of foreign-sourced materials creates vulnerabilities in the U.S. drug supply. …FDA has been working for over a decade to stimulate modernization QbD … an opportunity to reduce manufacturing costs while ensuring that consumers receive high- quality drug products…. with the proper strategies, revitalize pharmaceutical manufacturing in the United States. Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 10 http://www.pharmaceuticalonline.com/doc/cder-s-janet-woodcock- nobody-can-really-tell-me-if-fda-inspections-are-effective-0001 and http://www.fda.gov/NewsEvents/Testimony/ucm378343.htm
  • 11. FDA/CDER/OPQ = “Integrated” How did we get here? Pre-OPS to OPS to OPQ Assuring Same Quality Standards to Safeguard Clinical Performance Enhancing Science- and Risk-based Regulatory Approaches Transforming Qualitative- Quantitative and Expertise-based Product Quality Informatics Quality Metrics Question-based Review New Inspection Protocol Integration of Review, Inspection, Surveillance, Policy, and Research Team-based Integrated Quality Assessment (IQA) Program Alignment across FDA Encouraging Development of Emerging Technology Quality Information BLAs/NDAs/ANDA how does it link to patients? Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 11 CDER Office of Pharmaceutical Quality
  • 12. Immediate policy considerations: Appreciate complexity and uncertainty • Regulatory review – ask the right questions • An harmonized, integrated (review-inspection), life-cycle approach to analytical & process ‘validation’ • Product risk-assessment criteria when deviations from CGMPs occur • Quality metrics – supply chain reliability; distinguish between malicious and misguided behaviors • Focus on quality system & systems thinking – recognize the difference between complicated vs complex Risk-assessment & classification Quality Metrics Culture of Quality Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 12
  • 13. Invest in Pharmaceutical Technology Research & Education The Nation Needs a Comprehensive Pharmaceutical Engineering Education and Research System. Ajaz S. Hussain. Pharmaceutical Technology. September 2005 Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 13
  • 14. Summary Capability to satisfy regulatory requirements in Canada, US,…, at a lower development & manufacturing costs. Key drivers: EBITDA Exposed prevailing intra- and inter-agency heterogeneity and capacity constraints Globalization of costs Complexity and uncertainty in the assurance of ‘pharmaceutical quality’remains underappreciated Non- compliance: Global Issue Product risk-assessment criteria & Quality metrics – for supply chain reliability; distinguish between malicious and misguided behaviors Immediate policy considerations Catch-up with the paradigm long-shifted: “compounding” to “manufacturing”; “compendia” to “statistical confidence” Invest in Research & Education Manufacturing in Emerging Economies for Canada, USA,.. Ajaz S. Hussain, Ph.D. @ CIHR Best Brains Exchange, Ottawa, ON, January 22, 2016 14